ATXI Avenue Therapeutics, Inc.
USHealthcareAs of 2026-07-09 16:00
Why ATXI matters now
Avenue Therapeutics, Inc. (ATXI) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.32 with -3.39% on the session and $1.1M in market capitalization; recent performance reads 1-month +16.27% and YTD -52.14%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-695.0K, and EPS of $-0.21. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -101.1%.
The latest indexable market news headline is "Comparing Avenue Therapeutics (NASDAQ:ATXI) & Graybug Vision (NASDAQ:GRAY)" from Defense World.
Additional event context on this page matters because analyst consensus is Buy with a median target of $12.00; recent insider activity includes Fortress Biotech, Inc. filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.90
P/S
0.76
EV/EBITDA
0.65
DCF Value
$18.86
FCF Yield
-101.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
-149.3%
Net Margin
-124.8%
ROE
-65.8%
ROA
-71.0%
ROIC
-182.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-695.0K | $-0.21 |
| Q4 2025 | $0.00 | $-709.0K | $-0.22 |
| FY 2025 | $1.4M | $-2.9M | $-0.93 |
| Q3 2025 | $0.00 | $-683.0K | $-0.21 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$12.00
Target (Median)
$12.00
Target Range
$12.00 - $12.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.17
Avenue Therapeutics, Inc. functions as a specialized pharmaceutical enterprise, primarily dedicated to innovating and bringing to market medical therapies tailored for critical and intensive care environments within hospitals. Their leading product candidate is intravenous Tramadol, a synthetic opioid with a dual mechanism of action, currently undergoing Phase III clinical trials for the management of severe pain experienced by patients after surgery. Established in 2015, the company's operations are based in New York, New York.